MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Neurocrine Biosciences Company Profile (NASDAQ:NBIX)

Consensus Ratings for Neurocrine Biosciences (NASDAQ:NBIX) (?)
Ratings Breakdown: 9 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $62.11 (43.51% upside)

Analysts' Ratings History for Neurocrine Biosciences (NASDAQ:NBIX)
Show:
DateFirmActionRatingPrice TargetActions
6/8/2016Jefferies GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/7/2016Piper JaffrayReiterated RatingOverweight$96.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2016Leerink SwannReiterated RatingOutperform$63.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/8/2016Robert W. BairdReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/4/2016JPMorgan Chase & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/12/2016BMO Capital MarketsReiterated RatingOutperform$57.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/12/2016Cowen and CompanyReiterated RatingBuy$65.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/2/2015NomuraBoost Price TargetBuy$34.00 -> $43.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/2/2015Deutsche BankBoost Price TargetBuy$35.00 -> $45.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/4/2015BarclaysInitiated CoverageOverweight$60.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/5/2015RBC CapitalInitiated CoverageOutperform$40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/4/2014MKM PartnersReiterated RatingBuy$20.00 -> $22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/24/2014 forward)
Earnings History for Neurocrine Biosciences (NASDAQ:NBIX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
7/27/2016        
5/5/2016Q1($0.29)($0.22)$15.43 million$15.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/11/2016Q415($0.32)($0.34)$3.33 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/29/2015Q315($0.25)($0.40)$6.66 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/29/2015Q2($0.29)($0.28)$0.41 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2015Q115($0.30)($0.01)$19.76 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/9/2015Q414($0.24)($0.26)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2014Q314($0.21)($0.21)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2014Q214($0.18)($0.18)$0.12 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2014Q114($0.19)($0.17)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/6/2014Q413($0.17)($0.16)$0.79 million$0.73 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/29/2013Q313($0.20)($0.17)$0.79 million$0.73 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/25/2013Q2 2013($0.20)($0.18)$0.77 million$0.73 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2013Q1 2013($0.18)($0.18)$1.07 million$0.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/8/2013Q4 2012($0.08)$0.14$9.43 million$21.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/31/2012Q312($0.05)($0.05)$10.28 million$9.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/31/2012($0.03)($0.01)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2012($0.01)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/31/2011$0.19$0.56ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/28/2011$0.04$0.04ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/3/2011$0.05$0.05ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/10/2011$0.04$0.05ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Neurocrine Biosciences (NASDAQ:NBIX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.26)($0.25)($0.26)
Q2 20162($0.52)($0.47)($0.50)
Q3 20161($0.55)($0.55)($0.55)
Q4 20162($0.64)($0.62)($0.63)
(Data provided by Zacks Investment Research)
Dividend History for Neurocrine Biosciences (NASDAQ:NBIX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Neurocrine Biosciences (NASDAQ:NBIX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/25/2016Richard F PopsDirectorSell15,000$46.72$700,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2016Christopher Flint ObrienInsiderSell25,000$45.00$1,125,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/11/2016Kyle GanoInsiderSell41,770$44.02$1,838,715.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/6/2016Christopher Flint ObrienInsiderSell25,000$45.00$1,125,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/3/2016Haig P BozigianInsiderSell1,375$38.13$52,428.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/3/2016Kevin Charles GormanCEOSell3,125$38.04$118,875.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/3/2016Timothy P CoughlinCFOSell1,500$38.06$57,090.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/19/2016Haig P BozigianInsiderSell1,625$46.77$76,001.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/19/2016Kevin Charles GormanCEOSell3,750$46.70$175,125.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/19/2016Timothy P CoughlinCFOSell1,750$46.69$81,707.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/11/2016Haig P BozigianInsiderSell1,625$44.25$71,906.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/11/2016Kevin Charles GormanCEOSell3,750$44.17$165,637.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/11/2016Timothy P CoughlinCFOSell1,750$44.25$77,437.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/27/2015Dimitri E. GrigoriadisinsiderSell10,000$57.50$575,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/9/2015Darin LippoldtinsiderSell23,761$52.92$1,257,432.12View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/16/2015Haig P BozigianInsiderSell25,000$47.78$1,194,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/16/2015Kevin Charles GormanCEOSell33,500$47.77$1,600,295.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/18/2015Gary A. LyonsDirectorSell15,000$54.89$823,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/20/2015Dimitri E GrigoriadisInsiderSell19,646$55.00$1,080,530.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/20/2015Timothy P CoughlinCFOSell20,000$55.00$1,100,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/13/2015Dimitri E GrigoriadisInsiderSell10,000$50.00$500,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/13/2015Timothy P CoughlinCFOSell20,000$50.00$1,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/23/2015W Thomas MitchellDirectorSell15,000$49.35$740,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2015Christopher Flint ObrienInsiderSell10,000$45.00$450,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2015Timothy P CoughlinCFOSell60,000$45.08$2,704,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/24/2015Gary A LyonsDirectorSell30,000$41.53$1,245,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/24/2015Kevin Charles GormanCEOSell40,000$41.53$1,661,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/10/2015Dimitri E GrigoriadisInsiderSell20,000$35.00$700,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/16/2015Christopher Flint ObrienInsiderSell1,750$30.79$53,882.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/16/2015Kevin Charles GormanCEOSell3,750$30.79$115,462.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/12/2015Kevin Charles GormanCEOSell3,750$28.43$106,612.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/12/2015Kyle GanoInsiderSell1,250$28.41$35,512.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/12/2015Timothy P CoughlinCFOSell1,750$28.37$49,647.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/8/2015Dimitri E GrigoriadisInsiderSell30,000$27.35$820,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/8/2015Kevin Charles GormanCEOSell25,000$27.39$684,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/8/2015Timothy P CoughlinCFOSell10,000$27.25$272,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/5/2015Dimitri E GrigoriadisInsiderSell2,500$22.76$56,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2015W Thomas MitchellDirectorSell8,000$22.79$182,320.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/19/2014Christopher Flint ObrienInsiderSell20,000$24.02$480,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/19/2014Kevin Charles GormanCEOSell70,000$23.41$1,638,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/19/2014Timothy P CoughlinCFOSell30,000$23.46$703,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/17/2014Kyle GanoInsiderSell4,957$22.50$111,532.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2014Dimitri E GrigoriadisInsiderSell12,794$22.35$285,945.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/12/2014Kyle GanoInsiderSell4,043$22.50$90,967.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/11/2014Christopher Flint ObrienInsiderSell40,000$21.82$872,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2014Timothy P CoughlinCFOSell20,000$21.48$429,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2014W Thomas MitchellDirectorSell7,000$21.90$153,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/28/2014Timothy P CoughlinCFOSell10,000$20.14$201,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2014Christopher Flint ObrienInsiderSell5,463$19.53$106,692.39View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/31/2014Timothy P CoughlinCFOSell10,000$19.00$190,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/30/2014Timothy P CoughlinCFOSell20,000$18.31$366,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014W Thomas MitchellDirectorSell1,275$15.50$19,762.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2014Gary A LyonsDirectorSell20,000$15.66$313,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/17/2014Dimitri GrigoriadisInsiderSell25,000$20.00$500,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/10/2014Christopher Flint ObrienInsiderSell6,750$18.88$127,440.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/10/2014Kevin Charles GormanCEOSell3,750$18.57$69,637.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/10/2014Timothy CoughlinCFOSell1,750$18.56$32,480.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/7/2014Dimitri GrigoriadisInsiderSell25,000$17.50$437,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/7/2014Kevin Charles GormanCEOSell108,000$16.76$1,810,080.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/7/2014Timothy CoughlinCFOSell70,000$16.75$1,172,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/4/2013Kyle GanoInsiderSell2,400$15.61$37,464.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2013Christopher Flint ObrienInsiderSell5,000$16.00$80,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/21/2013Haig BozigianInsiderSell13,999$15.04$210,544.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/21/2013Timothy CoughlinCFOSell19,035$15.05$286,476.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/6/2013W Thomas MitchellDirectorSell1,531$14.70$22,505.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/5/2013Haig BozigianInsiderSell11,001$15.00$165,015.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/5/2013Timothy CoughlinCFOSell10,965$14.99$164,365.35View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/12/2013Christopher Flint ObrienInsiderSell5,000$14.50$72,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/28/2013Christopher Flint ObrienInsiderSell11,357$13.33$151,388.81View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/27/2013Haig P BozigianInsiderSell8,000$13.00$104,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/21/2013Dimitri E GrigoriadisInsiderSell46,837$12.51$585,930.87View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Neurocrine Biosciences (NASDAQ:NBIX)
DateHeadline
06/23/16 08:03 AMNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Current Analyst Ratings - Fiscal Standard
06/22/16 05:14 PMNotable Runners: QUALCOMM, Inc. (NASDAQ:QCOM), Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - NYSE Journal (press release)
06/20/16 07:01 AMNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Analyst Price Targets For The Coming Week - Fiscal Standard
06/11/16 08:13 AMAnalysts Review of Stocks: Cerus Corporation (NASDAQ:CERS) , Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - Street Updates
06/11/16 08:13 AMStocks Earnings Report: Big Lots Inc. (NYSE:BIG), Neurocrine Biosciences Inc. (NASDAQ:NBIX) - Beacon Chronicle
06/06/16 09:03 AMNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock Update & Estimates - Stock Tick Tock
06/06/16 09:03 AMTrading Overview of Two Stocks: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) , Sangamo BioSciences, Inc. (NASDAQ ... - Street Updates
06/05/16 08:00 AMPerformance Review for Neurocrine Biosciences Inc. (NASDAQ:NBIX) - HNN
06/05/16 08:00 AMNeurocrine Biosciences, Inc. (NBIX) Given “Buy” Rating at JPMorgan Chase & Co. - Let Me Know About This
06/04/16 08:11 AMPerceptive Advisors LLC Increased Neurocrine Biosciences INC (NASDAQ:NBIX) by $8.77 Million as Shares Declined - CCH Daily News
06/03/16 05:50 PMBuy Sell or Hold? - Neurocrine Biosciences Inc. (NASDAQ:NBIX), TE Connectivity Ltd. (NYSE:TEL) - Beacon Chronicle
06/02/16 05:45 PMStock Review and Earnings Check on Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - HNN - Stock Review and Earnings Check on Neurocrine Biosciences, Inc. (NASDAQ:NBIX)HNNInvestors and analysts are typically super focused on company earnings numbers when they are reported. Company earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Neurocrine Biosciences, Inc.and more »
06/02/16 03:05 PMNeurocrine Biosciences to Present at the Jefferies 2016 Healthcare Conference - [at noodls] - SAN DIEGO, June 2, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the Jefferies 2016 ...
06/02/16 08:18 AMNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Do Brokers Advise Buy, Sell Or Hold? - Share Trading News - Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Do Brokers Advise Buy, Sell Or Hold?Share Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX). The latest reports which are currently in issue on Thursday 2nd of June state 0 analysts have a rating of “strong buy”, 0 ...Microsoft Corporation (NASDAQ:MSFT) to cut 1850 smartphone workers: Weibo Corporation (NASDAQ:WB ...Benchmark Monitorall 3 news articles »
06/01/16 05:52 PMNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Set To Release Quarterly Earnings - Investor Newswire - Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Set To Release Quarterly EarningsInvestor NewswireAccording to a group of market experts surveyed by Zacks Research, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is projected to report earnings of $-0.69 for its recent quarter. The company plans to release its quarterly report on or around 2016-08-03.and more »
06/01/16 08:17 AMShare Rating Focus on Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - HNN - Share Rating Focus on Neurocrine Biosciences, Inc. (NASDAQ:NBIX)HNNPresently, Wall Street analysts have given a consensus stock rating of 1 on shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Covering analysts will typically provide Buy, Sell, or Hold recommendations based on extensive research. This consensus ...
05/31/16 03:39 PMTeva’s Huntington Drug Hits A Snag, Lifting Rival Neurocrine -
05/26/16 08:48 PMEarnings Review and Stock Rundown for Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - Wall Street Hints and News - Earnings Review and Stock Rundown for Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Neurocrine Biosciences, Inc. (NASDAQ:NBIX ...Hold Calls Count For Neurocrine Biosciences, Inc. (NASDAQ:NBIX) At 0Markets Dailyall 349 news articles »
05/26/16 08:48 PMNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Closes At $46.56 - Investor Newswire - Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Closes At $46.56Investor NewswireYesterday, the stock of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) closed at $46.56 after opening at $46.47 and registering high of $46.47 and low of $44.65. The last price is $-13.18 off 1-year high of $58.46 and $14.03 away from low of $31.25 during ...Today Brokerage Opinions: Opexa Therapeutics, Inc. (NASDAQ:OPXA), Neurocrine Biosciences, Inc. (NASDAQ:NBIX)WsNews 4investorsall 3 news articles »
05/24/16 06:08 AMNEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles of I -
05/23/16 08:27 AMMost Recent Stocks Movements: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) , CONMED Corporation (NASDAQ ... - Street Updates - Street UpdatesMost Recent Stocks Movements: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) , CONMED Corporation (NASDAQ ...Street UpdatesOn 5/20/2016, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) ended trading session higher at $47.89 with +2.07%. The company traded a volume of 1.11 million shares as comparison to average volume of 1.06 million shares. During the 52 –week period, the ...and more »
05/20/16 03:32 PMHealthcare Stock under Consideration: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - News Oracle - News OracleHealthcare Stock under Consideration: Neurocrine Biosciences, Inc. (NASDAQ:NBIX)News OracleBy looking at Neurocrine Biosciences, Inc. (NASDAQ:NBIX) YTD (year to date) performance, the stock shows Negative value of -17.06%. If the YTD value is Negative, it means that the stock is trading poorly. If the YTD value is Positive, this means the ...Neurocrine Biosciences Incorporated (NASDAQ:NBIX) Shorted Shares Increased 11.08% After Market SellingFranklin IndependentNeurocrine Biosciences (NBIX) Director Thomas to RetireStreetInsider.comall 4 news articles »
05/20/16 08:13 AMNeurocrine Biosciences Announces the Retirement of W. Thomas Mitchell from the Board of Directors - [at noodls] - SAN DIEGO, May 20, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that W. Thomas Mitchell has notified the Company that he is retiring from the Board of Directors effective ...
05/19/16 08:41 PMNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Trading Up – Insiders Selling, Short Interest Growing - There has been some selling insider activity on Neurocrine Biosciences, Inc. (NASDAQ:NBIX) recently. Christopher Flint Obrien, Chief Medical Officer sold $1,125,000 worth of shares at an average price of $45.00 on May 16th. That brings the Chief Medical ...
05/19/16 06:44 PMETF’s with exposure to Neurocrine Biosciences, Inc. : May 19, 2016 -
05/18/16 08:38 PMNeurocrine Biosciences Inc. (NBIX) Jumps 5.19% on May 18 - Equities.com - Neurocrine Biosciences Inc. (NBIX) Jumps 5.19% on May 18Equities.comNeurocrine Biosciences Inc. (NBIX) was among the biggest gainers on the Russell 2000 for Wednesday May 18 as the stock popped 5.19% to $45.64, representing a gain of $2.25 per share. Some 1.58 million shares traded hands on 13,564 trades, ...and more »
05/18/16 03:30 PMInvestors Reviewing Stocks: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) , Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - Street Updates - Investors Reviewing Stocks: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) , Jazz Pharmaceuticals plc (NASDAQ:JAZZ)Street UpdatesNeurocrine Biosciences, Inc. (NASDAQ:NBIX) diminished -4.93%, closing at $43.39 after floating between $43.19 and $45.90. The company has market capitalization of $3.76B. It has twelve month low of $31.25 and twelve month high of $58.46. The recent ...Stock Seeing Gains in Session: Neurocrine Biosciences Inc. (NASDAQ:NBIX)The PostRevenue Update on Neurocrine Biosciences(NASDAQ:NBIX)Trade CallsAnalysts Have Conflicting Sentiments on These Healthcare Companies: Amag Pharmaceuticals (NASDAQ: AMAG ...Markets.coall 6 news articles »
05/18/16 07:41 AMRevenue Update on Neurocrine Biosciences(NASDAQ:NBIX) - Trade Calls - Revenue Update on Neurocrine Biosciences(NASDAQ:NBIX)Trade CallsNeurocrine Biosciences Inc. is engaged in the development of pharmaceutical products focused on neurological and endocrine based diseases and disorders. The Company's two lead late-stage clinical programs are elagolix a gonadotropin releasing ...
05/17/16 03:31 PMNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Reports Basic Consolidated EPS At $-1.0525 - Investor Newswire - Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Reports Basic Consolidated EPS At $-1.0525Investor NewswireFrom the parent firm, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) diluted EPS came at $-1.0525 for the year ended 2015-12-31. For the quarter ended 2015-12-31 it came at $-1.0525. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) posted net basic EPS of ...
05/16/16 03:22 PMNotable Stocks within Investor Radar: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) , Universal Health Services, Inc ... - Street Updates - Notable Stocks within Investor Radar: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) , Universal Health Services, Inc ...Street UpdatesOn 5/13/2016, shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) rose +1.65% in trading session and finally closed at $43.65. The company most recent volume stood at 766.12 thousand shares as compared to its average volume of 1.04 million shares.
05/16/16 03:22 PMNeurocrine Biosciences Breaks Above 200-Day Moving Average - Bullish for NBIX - Nasdaq - NasdaqNeurocrine Biosciences Breaks Above 200-Day Moving Average - Bullish for NBIXNasdaqIn trading on Monday, shares of Neurocrine Biosciences, Inc. (Symbol: NBIX) crossed above their 200 day moving average of $45.90, changing hands as high as $46.07 per share. Neurocrine Biosciences, Inc. shares are currently trading up about 5.1% on ...Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Broker Price Targets For The Coming WeekShare Trading Newsall 6 news articles »
05/13/16 03:50 PMNeurocrine Biosciences, Inc. (NASDAQ:NBIX) One-Year Mean Price Target At $68.555 - RealistInvestor.com - Neurocrine Biosciences, Inc. (NASDAQ:NBIX) One-Year Mean Price Target At $68.555RealistInvestor.comSell-side analysts are confident on the future outlook of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) stock. As of 2016-05-12, the stock has an ABR of 1 rating, where number 5 denotes a Strong Sell and 1 Strong Buy. The ABR is reached on the basis of ...and more »
05/13/16 02:04 AMState Street Corp Buys A Lot More Neurocrine Biosciences, Inc. (NBIX) Stock - Finance Daily - State Street Corp Buys A Lot More Neurocrine Biosciences, Inc. (NBIX) StockFinance DailyState Street Corp says it bought 499,687 shares last quarter increasing its holdings in Neurocrine Biosciences, Inc. by 22.9%. Its stake was worth $106,077,000 a decrease of 14.1% as of quarter end. Here are a few other firms who have updated their ...
05/12/16 12:04 PMNEUROCRINE BIOSCIENCES INC Financials -
05/12/16 12:01 PMNeurocrine Biosciences, Inc. :NBIX-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/10/16 08:55 PMConsensus Rating Review for Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - B.O.D.Y Confidential - Consensus Rating Review for Neurocrine Biosciences, Inc. (NASDAQ:NBIX)B.O.D.Y ConfidentialEquity research analysts currently have a consensus rating of 1 on shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Sell-side analysts will typically rate a company's stock based on extensive research. These ratings usually translate into a Buy ...and more »
05/09/16 03:45 PMInvestors EPS Watch List: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - News Oracle - NYSE Journal (press release)Investors EPS Watch List: Neurocrine Biosciences, Inc. (NASDAQ:NBIX)News OracleLast Trade: The Company rose 0.52% and finished at $42.87. The daily volume was measured at 1.12 million shares. The 52-week high of the share price is $58.46 and the 52-week low is $31.25. The company has a market cap of $3.69 billion. Its latest ...Neurocrine Biosciences, Inc.(NASDAQ:NBIX) &Mast Therapeutics Inc(NYSEMKT:MSTX) Healthcare Traders RecapWall Street 24Top Gainer Today: Neurocrine Biosciences Inc. (NASDAQ:NBIX)The PostWorth Watching Stocks on the Run: ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC), Neurocrine Biosciences, Inc ...NYSE Journal (press release)all 5 news articles »
05/09/16 02:30 PMNBIX: NDA for Valbenazine in Tardive Dyskinesia to be Filed in 2016… -
05/08/16 08:56 PMNeurocrine Biosciences (NBIX) Will Present Additional NBI-98854 Kinect 1, Kinect 2 Data at APA 2016 - Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced that four abstracts representing additional data from both the Kinect 3 and Kinect 2 tardive dyskinesia clinical trials of valbenazine will be presented at the American Psychiatric Association Annual ...
05/07/16 03:30 PMPortfolio Of Healthcare Movers: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) , Regulus Therapeutics Inc. (NASDAQ ... - Is stories - Is storiesPortfolio Of Healthcare Movers: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) , Regulus Therapeutics Inc. (NASDAQ ...Is storiesNeurocrine Biosciences, Inc. (NASDAQ:NBIX) increased +0.52% to $42.87 while traded 1.13 million shares on 5/6/2016. The stock price negotiated for value between $40.86 to $44.07 in recent trading session. During the past 52 weeks, the stock's price ...Neurocrine Biosciences Incorporated (NASDAQ:NBIX) Shorts Decreased by 6.43% After Short CoveringFranklin Independentall 2 news articles »
05/06/16 03:46 PMNeurocrine Biosciences, Inc. (NASDAQ:NBIX) ABR Of 1 - RealistInvestor.com - Neurocrine Biosciences, Inc. (NASDAQ:NBIX) ABR Of 1RealistInvestor.comAnalysts have a buy call on Neurocrine Biosciences, Inc. (NASDAQ:NBIX) stock. As of 2016-05-05, it had an ABR of 1. The rating is fixed on a scale of 1-5. Here three stands for hold call. This analyst brokerage rating computation is based on 9 calls.and more »
05/06/16 02:34 PMNeurocrine Biosciences Announces Additional Valbenazine (NBI-98854) Data to be Presented at the American Psychiatric Association's 2016 Annual Meeting in Atlanta - [at noodls] - SAN DIEGO, May 6, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that four abstracts representing additional data from both the Kinect 3 and Kinect 2 tardive dyskinesia ...
05/06/16 02:00 PMNeurocrine Biosciences to Present at the Bank of America Merrill Lynch 2016 Health Care Conference - [PR Newswire] - SAN DIEGO, May 6, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas. Listeners are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software. A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for one month.
05/06/16 11:31 AMEdited Transcript of NBIX earnings conference call or presentation 5-May-16 9:00pm GMT -
05/06/16 08:58 AMNeurocrine Reports Added NBI-98854 Data Will Be Presented at APA Meeting - Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that four abstracts representing additional data from both the Kinect 3 and Kinect 2 tardive dyskinesia clinical trials of valbenazine will be presented at the American Psychiatric Association Annual Meeting in May. The four posters will include an evaluation of the impact of valbenazine on the psychiatric stability of subjects with underlying schizophrenia, schizoaffective disorder or mood disorder (including bipolar disorder or major depressive disorder), data assessing the effect of valbenazine stratified by baseline tardive dyskinesia severity, and an evaluation of valbenazine with concomitant antipsychotic ...Full story available on Benzinga.com
05/05/16 09:07 PMBroker Outlook For Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - Share Trading News - Broker Outlook For Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Share Trading NewsThe Company's two lead late-stage clinical programs are elagolix, a gonadotropin releasing hormone (GnRH) antagonist for women's health that is partnered with AbbVie Inc. (AbbVie), and a vesicular monoamine transporter 2 (VMAT2) inhibitor for the ...
05/05/16 05:22 PMNeurocrine reports 1Q loss -
05/05/16 03:59 PMEarnings Outlook on Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - B.O.D.Y Confidential - Earnings Outlook on Neurocrine Biosciences, Inc. (NASDAQ:NBIX)B.O.D.Y ConfidentialAnalysts and investors will be anticipating Neurocrine Biosciences, Inc. (NASDAQ:NBIX)'s next earnings release which is expected to be posted on or around 2016-05-05. Sell-side research firms on Wall Street are expecting that the company will post EPS ...and more »
05/05/16 03:59 PMInvestors Reviewing Stocks: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) , Surgical Care Affiliates, Inc. (NASDAQ:SCAI) - Street Updates - Investors Reviewing Stocks: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) , Surgical Care Affiliates, Inc. (NASDAQ:SCAI)Street UpdatesOn 5/4/2016, shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) fell -4.75% in trading session and finally closed at $42.91. The company most recent volume stood at 961.22 thousand shares as compared to its average volume of 1.16 million shares.and more »
05/05/16 03:03 PM4:03 pm Neurocrine Biosci beats by $0.07, misses on revs -
About Neurocrine Biosciences

Neurocrine Biosciences logoNeurocrine Biosciences, Inc. is engaged in the development of pharmaceutical products focused on neurological and endocrine-based diseases and disorders. The Company's two lead late-stage clinical programs are Elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for women's health that is partnered with AbbVie Inc. (AbbVie), and NBI-98854 (valbenazine), a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. The Company focuses on developing NBI-640756 against Essential tremor. Its research and development focuses on addressing diseases and disorders of the central nervous and endocrine systems, which include therapeutic categories ranging from hypothalamic-pituitary-adrenal (HPA) disorders to stress-related disorders and neurological/neuropsychiatric diseases. Its Corticotropin-Releasing Factor (CRF) is a hypothalamic hormone released directly into the hypophyseal portal vasculature.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drugs - Generic
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: NBIX
  • CUSIP: 64125C10
Key Metrics:
  • Previous Close: $43.28
  • 50 Day Moving Average: $46.48
  • 200 Day Moving Average: $44.22
  • P/E Ratio: N/A
  • P/E Growth: 2.39
  • Market Cap: $3.75B
  • Current Quarter EPS Consensus Estimate: $-1.95 EPS
Additional Links:
Neurocrine Biosciences (NASDAQ:NBIX) Chart for Friday, June, 24, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha